The Medtronic Newsroom is designed to assist media in finding news and information about our company.
Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.
Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.
More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.
Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 46,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.
|09/02/14||Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference|
|MINNEAPOLIS - Sept 2, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Morgan Stanley Global Healthcare Conference, September 8, 2014, in New York. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 3:25 p.m. EDT (2:25 p.m. CDT). A live audio webcast of the presentation will be available on September 8, 2014, by clicking on the Invest... |
|08/28/14||Medtronic Receives Clearance for the SHILLA(TM) Growth Guidance System|
|First U.S. Growth Guidance System Cleared to Treat Scoliosis with Children's Needs in Mind MEMPHIS, TN - Aug. 28, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the 510(k) clearance and launch of the SHILLA(TM) Growth Guidance System. The system is designed for treatment of skeletally immature pediatric patients less than 10 years of age diagnosed with severe, progressive, life-threatening, early-onset spinal deformities. The SHILLA(TM) Growth Guidance System is a new growth-sparing tech... |
|08/27/14||Medtronic Announces First Implants in Largest-Ever, Global Trial of Cardiac Resynchronization Therapy|
|Post-Market Clinical Trial Will Assess Superiority of the AdaptivCRT® Feature Compared to Standard CRT MINNEAPOLIS - Aug. 27, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the first implants in a clinical trial that will compare patient and healthcare system outcomes - including patient mortality and hospitalizations - in heart failure patients who have cardiac resynchronization therapy (CRT) devices with the AdaptivCRT® feature enabled versus patients receiving standard CRT. The AdaptRespo... |
|Receive E-mail Alerts |
|Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.|